Increased serum interleukin‐17 levels in patients with myasthenia gravis
- 16 February 2011
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 44 (2), 278-280
- https://doi.org/10.1002/mus.22070
Abstract
It has been suggested that interleukin-17 (IL-17) plays a crucial role in the development of several autoimmune diseases. However, there are no data about the relationship between myasthenia gravis and IL-17. The aim of this study was to measure the concentration of IL-17 and determine whether levels depend on the severity of MG. Serum IL-17 concentrations were measured in 25 patients. IL-17 concentrations were higher in generalized MG compared with controls and correlated with anti-acetylcholinesterase receptor antibody titers. Muscle Nerve, 2011Keywords
This publication has 13 references indexed in Scilit:
- IL‐6: Regulator of Treg/Th17 balanceEuropean Journal of Immunology, 2010
- Research advancement in immunopathogenesis of myasthenia gravisNeuroscience Bulletin, 2010
- Current Views on the Roles of Th1 and Th17 Cells in Experimental Autoimmune EncephalomyelitisJournal of Neuroimmune Pharmacology, 2010
- Phenotypical and functional characterization of T helper 17 cells in multiple sclerosisBrain, 2009
- Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravisImmunology, 2009
- Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosusNature Immunology, 2009
- Correlating extent of neuromuscular instability with acetylcholine receptor antibodiesMuscle & Nerve, 2009
- A Potential Role for B-Cell Activating Factor in the Pathogenesis of Autoimmune Myasthenia GravisArchives of Neurology, 2008
- Serum BAFF expression in patients with myasthenia gravisJournal of Neuroimmunology, 2008
- Function of circulating antibody to acetylcholine receptor in myasthenia gravisNeurology, 1978